226 related articles for article (PubMed ID: 37813891)
21. Mutational landscape of homologous recombination-related genes in small-cell lung cancer.
Wu S; Zhang Y; Zhang Y; Chen LH; Ouyang HF; Xu X; Du Y; Ti XY
Cancer Med; 2023 Feb; 12(4):4486-4495. PubMed ID: 36053931
[TBL] [Abstract][Full Text] [Related]
22. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
23. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4
Saleh R; Toor SM; Khalaf S; Elkord E
Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877
[No Abstract] [Full Text] [Related]
24. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
[TBL] [Abstract][Full Text] [Related]
26. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
27. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
[TBL] [Abstract][Full Text] [Related]
28. Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer.
Ma D; Chen SY; Ren JX; Pei YC; Jiang CW; Zhao S; Xiao Y; Xu XE; Liu GY; Hu X; Liang XZ; Yu KD; Li DQ; Jiang YZ; Shao ZM
J Natl Cancer Inst; 2021 Jul; 113(7):884-892. PubMed ID: 33151324
[TBL] [Abstract][Full Text] [Related]
29. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
[TBL] [Abstract][Full Text] [Related]
30.
Jouali F; El Ansari FZ; Marchoudi N; Barakat A; Zmaimita H; Samlali H; Fekkak J
Int J Mol Epidemiol Genet; 2020; 11(1):16-25. PubMed ID: 32714499
[TBL] [Abstract][Full Text] [Related]
31. Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study.
Yi D; Xu L; Luo J; You X; Huang T; Zi Y; Li X; Wang R; Zhong Z; Tang X; Li A; Shi Y; Rao J; Zhang Y; Sang J
Hum Genomics; 2019 Jan; 13(1):4. PubMed ID: 30630526
[TBL] [Abstract][Full Text] [Related]
32. Genetic variants of BRCA1 and BRCA2 genes in cats with mammary gland carcinoma.
Govoni VM; Da Silva TC; Guerra JM; Pereira IVA; Queiroga FL; Cogliati B
Vet Comp Oncol; 2021 Jun; 19(2):404-408. PubMed ID: 33576549
[TBL] [Abstract][Full Text] [Related]
33. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
Shrestha R; Prithviraj P; Anaka M; Bridle KR; Crawford DHG; Dhungel B; Steel JC; Jayachandran A
Front Oncol; 2018; 8():269. PubMed ID: 30057891
[TBL] [Abstract][Full Text] [Related]
34. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
[TBL] [Abstract][Full Text] [Related]
35. Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer.
Ferreira EN; Brianese RC; de Almeida RVB; Drummond RD; de Souza JE; da Silva IT; de Souza SJ; Carraro DM
Transl Oncol; 2019 Nov; 12(11):1453-1460. PubMed ID: 31419696
[TBL] [Abstract][Full Text] [Related]
36. The fate of BRCA1-related germline mutations in triple-negative breast tumors.
Kotoula V; Fostira F; Papadopoulou K; Apostolou P; Tsolaki E; Lazaridis G; Manoussou K; Zagouri F; Pectasides D; Vlachos I; Tikas I; Lakis S; Konstantopoulou I; Pentheroudakis G; Gogas H; Papakostas P; Christodoulou C; Bafaloukos D; Razis E; Karavasilis V; Bamias C; Yannoukakos D; Fountzilas G
Am J Cancer Res; 2017; 7(1):98-114. PubMed ID: 28123851
[TBL] [Abstract][Full Text] [Related]
37. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Tazzite A; Jouhadi H; Benider A; Nadifi S
Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
[TBL] [Abstract][Full Text] [Related]
38. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
Voutsadakis IA; Stravodimou A
Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
[TBL] [Abstract][Full Text] [Related]
39. Triple-negative breast cancer: promising prognostic biomarkers currently in development.
Sukumar J; Gast K; Quiroga D; Lustberg M; Williams N
Expert Rev Anticancer Ther; 2021 Feb; 21(2):135-148. PubMed ID: 33198517
[No Abstract] [Full Text] [Related]
40. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
